Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is expected to see increased demand and revenue growth due to their innovative liquid biopsy technology and growing partnerships with biopharmaceutical companies. Despite facing competition in the market, the company has shown strong financial performance and has a solid pipeline for future growth based on their recent achievements and plans for expansion. However, there are potential risks to consider, such as legal and regulatory challenges, which could impact their financial performance in the future.

Bears say

Guardant Health is currently experiencing a flurry of positive catalysts, including its recent FDA approval for G360CDx and inclusion in both the American Cancer Society and NCCN guidelines for colon cancer screening. However, our negative outlook stems from concerns over deceleration in Guardant's core product, Guardant360, as well as uncertainties around the sustainability of Shield's high pricing and volume growth. Additionally, the company's financials may face pressure as reimbursement for multi-cancer screening tests is set to be linked to the pricing of a competitor, lowering potential rates for Guardant's Shield test.

GH has been analyzed by 23 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 23 analysts, GH has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $187.87, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $187.87, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.